According to a research report titled ‘Cancer Diagnostics Market Size By Application (Tumor Biomarkers Tests, Imaging {Ultrasound and Radiology, Mammography, MRI Scan, PET Scan, CT Scan, SPECT & Others}, Biopsy, Liquid Biopsy, Immunohistochemistry, In Situ Hybridization), By Cancer Type (Bladder Cancer, Breast Cancer, Colon and Rectal Cancer, Endometrial Cancer, Kidney Cancer, Leukemia, Liver-Lung Cancer, Melanoma, Non-Hodgkin Lymphoma, Pancreatic Cancer, Prostate Cancer, Thyroid Cancer), By End-use (Hospitals, Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2020 – 2026’, available with MarketStudyReport, cancer diagnostics market is anticipated to grow momentously through 2026.
 

Increasing obesity rate, unhealthy diet patterns, excessive smoking, and alcohol consumption, all leading to rising prevalence of cancer is majorly driving the global cancer diagnostics market growth. Also, government initiatives for improved disease cognizance, technological advancements, and setup of new diagnostic centers in various nations are adding to the industry share.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/859978/
 

In terms of application ambit, liquid biopsy segment accounted for 2.6% market share in 2019. It involves analyzing tumor using biomarkers found in bodily fluids such as blood. Liquid biopsy has been increasingly popular in recent years and is speculated to become a standard clinical tool.
 

In regard to cancer type, bladder cancer diagnostics industry segment gained a revenue share of 5.8% in 2019 and is expected to grow momentously over the analysis timeframe, due to rising cases of bladder cancer, with prevalence of smoking among the populace.  
 

Speaking of end-use terrain of cancer diagnostics market, diagnostic imaging centers generated revenues worth USD 17.6 billion in 2019, owing to the fact that these facilities use cutting-edge technology and employ highly qualified specialists to perform the necessary tests. They are also known for delivering outcomes faster than other settings.  
 

Considering the regional aspect, Latin America is expected to become a lucrative growth ground for the industry partakers in the coming years, due to high occurrence of cancer in the region. By 2026, Latin American market is expected to reach USD 7.3 billion, with regional governments investing heavily in research to discover new diagnostic tools, alongside well-established healthcare infrastructure.
 

The key players in the marketplace are Abbott Laboratories, Agilent Technologies Inc,, Bio-Rad Laboratories, AB Sciex Pte. Ltd., Biocartis S.A., Becton Dickinson and Company, Biocare Medical LLC, bioMérieux S.A., GE Healthcare, Cancer Genetics Inc., Janssen Diagnostics LLC (Johnson & Johnson), Hologic Inc., Leica Biosystem Nussloch GmbH (Danaher Corporation), Qiagen N.V., Myriad Genetics Inc., F. Hoffmann-La Roche Ltd, Sysmex Corporation, Siemens Healthineers AG, and Thermo Fischer Scientific.